UK chemical industry warns of £1bn cost to duplicate EU regime – FT

  • From January 1, the safety registrations of certain chemicals used to make products in the UK (currently held in the Reach registration database run by the European Chemicals Agency (Echa) in Helsinki) will need to be re-registered with a new UK equivalent.
  • Registering a single chemical in the new UK Reach database could cost up to £300,000 if companies are required to buy “letters of access” to use the vast banks of test data held by Echa — information that is expensive to produce and often owned by third parties.
  • Crucial to shrinking the new registration costs for UK companies will be whether negotiators can broker a data-sharing agreement between Echa and the UK authorities to remove the need for the letters of access.
  • Steve Elliott, chief executive of the Chemical Industries Association, said that unless a data-sharing deal was done with Brussels the new system would add more than £1bn in costs to companies, just to duplicate existing registrations.
  • The request for a data-sharing agreement is supported by both the European Chemical Industry Council and the Chemical Industries Association. But EU officials are cautious about the prospects for such a deal.

UK urges medicine suppliers to stockpile before Brexit transition ends – Reuters

  • The UK government has urged medicine suppliers to prepare for the country’s exit from the EU single market and customs union by building up six weeks’ worth of stocks in case of disruption to imports.
  • “We recognise that global supply chains are under significant pressure, exacerbated by recent events with COVID-19,” the health ministry said in a letter to medicine suppliers which it published on Monday.
  • “However, we encourage companies to make stockpiling a key part of contingency plans, and ask industry, where possible, to stockpile to a target level of six weeks’ total stock on UK soil.”
  • The ministry said it had built up a centralised stock of fast-moving medical devices and clinical consumables in the run-up to the exit from the EU on Jan. 31.
Author

Jessica's practice focuses on international trade and anti-bribery work, encompassing customs, export control and sanctions matters. Jessica's trade work includes advising international clients on fast-moving and evolving EU and UN sanctions, notably in respect of Iran and Russia, and on compliance with UK and EU export controls. Her trade experience also includes advising on tariff classification and customs valuations. Jessica's anti-bribery experience includes assisting with investigations, and advising clients on compliance with anti-bribery laws. Jessica has also taken a lead role in monitoring Brexit-related developments; analysing how they will affect the UK's trading position generally, and clients' businesses specifically. She has helped clients begin to conduct risk assessments of how Brexit will impact their businesses, and has assisted them in developing tailored Brexit strategies. Jessica also presents at various seminars, webinars, and conferences on the complexities of Brexit. Jessica advises global clients on complex issues arising from international transactions and works with clients across a number of sectors including pharmaceuticals, defence, finance, aviation, energy, and telecommunications. Jessica has also worked previously in Paris, and is fluent in French.

Write A Comment